Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
How should clinicians define disease control, select therapy, and personalize treatment for people living with acromegaly? A new three-part podcast series from The Pituitary Society explores these questions through the lens of the updated international consensus recommendations on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37).
In this engaging discussion, we touch on why muscles stay weak in acromegaly even after the disease is under control, and why hypercortisolism keeps turning up in more people than anyone used to expect. Dr. Valassi’s earlier work on acromegaly and muscles got a lot of attention from PWN readers.
I sat down with Dr. Leena Shahla, medical director of the Duke Pituitary Center to talk about the latest developments from ENDO 2026. Many in of our readers will remember her from an earlier Pituitary World News Podcast conversation with our co-founder, Dr. Lewis Blevins, on the tricky business of distinguishing pseudo-Cushing’s from the real thing. This time, the focus was the fast-moving world of acromegaly therapy.
We ran into Sonnie Kim, Camurus’ head of Medical Affairs, at this year’s ENDO2026 conference in Chicago and asked her about the latest on CAM2029, the long-acting octreotide subcutaneous depot delivered by a pre-filled pen, built on the company’s FluidCrystal technology. The product is approved in Europe under the brand name Oczyesa and is still awaiting US approval.
In this episode, Isabelle Petit, senior manager at Debiopharm, a leading development company headquartered in Lausanne, Switzerland, discusses the latest data from a clinical trial of a three-month formulation for acromegaly treatment, highlighting its impact on patient quality of life and treatment satisfaction.
For those living with acromegaly, the daily challenges of managing their condition can be overwhelming. This podcast explores this new formulation of Octreotide that promises a significant shift in treatment protocols. With insights from Anne, we’ll dive into the details of this innovative approach, how it works, and why it matters for patients.
In an important new development Swiss-based Debiopharm entered a Phase 3 trial of a new Octreotide formulation. The company is currently recruiting patients for the study. Debio 4126 is a sustained-release formulation designed to improve the convenience of somatostatin analogue (SSA) therapy for the treatment of acromegaly.
Could artificial intelligence and machine learning recognize the early, subtle changes in people’s faces associated with the hormonal disease acromegaly? New research spearheaded by Dr. Manel Puig-Domingo and outlined in a recent paper published in the journal PITUITARY raises the possibility that AI algorithms and machine learning could provide a game-changing approach to the early diagnosis of this complex disease, which now takes an average of 6 to 10 years to diagnose.
Crinetics announced today that the FDA has approved PALSONIFY™, the first once-daily oral therapy to treat acromegaly. The company announced the drug will be available in early October.